CureVac N.V.

NASDAQ:CVAC

2.75 (USD) • At close November 13, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q1
Revenue 14.43612.37321.98816.4837.5797.12911.68911.21220.14624.37341.22529.3422.39510.0365.16234.5493.1196.8161.0963.156
Cost of Revenue 40.72341.68959.76324.28125.85420.63580.00124.07942.68137.23270.018115.02137.39615.767.1241.9730.3995.4759.1116.9997.558
Gross Profit -26.287-29.316-37.775-7.798-18.275-13.506-68.312-12.867-22.535-12.859-28.793-85.681-15.001-5.73-1.1243.18934.15-2.356-2.295-5.903-4.402
Gross Profit Ratio -1.821-2.369-1.718-0.473-2.411-1.895-5.844-1.148-1.119-0.528-0.698-2.92-0.67-0.571-0.1870.6180.988-0.755-0.337-5.386-1.395
Reseach & Development Expenses 31.09327.82529.37327.24530.86824.25127.61612.51211.63610.786531.17948.461131.281104.98637.47134.5730.86610.90212.5775.34910.862
General & Administrative Expenses 13.37216.69421.59615.83618.9819.59723.56621.98523.11520.32814.09522.45531.22919.42211.8829.42213.9819.74413.6799.1245.471
Selling & Marketing Expenses 0.0750.1050.0820.1450.0880.1080.0970.093-0.0440.2710.5110.2030.5520.477-0.076-0.20.6790.331.27-0.0240.198
SG&A 13.44716.79923.25315.98119.06819.70523.66322.07823.07120.59914.60622.65831.78119.89911.8069.22214.6610.07414.9499.15.669
Other Expenses 2.79300003.2032.3944.9233.977-28.976-569.067-13.706-30.238-14.782-3.719-3.845-7.377-0.1175.249-1.2070.792
Operating Expenses 47.33344.92352.62646.71353.70247.15953.67339.51338.6842.409-23.28257.413132.824110.10352.639.94738.14920.85932.77513.24217.323
Operating Income -73.62-73.317-90.401-54.036-71.801-60.355-121.51-52.38-60.299-15.268-5.511-143.094-147.825-115.833-46.6-36.758-3.2-23.216-35.071-19.145-21.725
Operating Income Ratio -5.1-5.926-4.111-3.278-9.474-8.466-10.395-4.672-2.993-0.626-0.134-4.877-6.601-11.549-7.767-7.121-0.093-7.443-5.145-17.468-6.884
Total Other Income Expenses Net 2.3773.431.5265.3614.4142.937-7.244.7352.7280.0790.952-0.418-4.3683.599-10.6170.068-8.807-0.678-0.8360.1410.559
Income Before Tax -71.243-69.887-84.269-48.675-67.387-57.418-128.75-47.646-57.57-15.189-4.559-143.512-152.193-112.234-57.3-36.69-12.007-23.894-35.907-19.004-21.166
Income Before Tax Ratio -4.935-5.648-3.832-2.953-8.891-8.054-11.015-4.25-2.858-0.623-0.111-4.891-6.796-11.19-9.55-7.108-0.348-7.661-5.268-17.339-6.707
Income Tax Expense 1.3010.6660.1610.0060.0260.0010.034-0.0780.014-0.096-2.6230.512-0.1371.4660.8890.144-1.716-0.0440.083-0.6440.142
Net Income -72.543-70.553-84.43-48.681-67.414-57.419-128.784-47.568-57.584-15.093-1.936-144.024-152.056-113.7-57.3-36.834-10.291-23.85-35.99-18.36-21.308
Net Income Ratio -5.025-5.702-3.84-2.953-8.895-8.054-11.018-4.243-2.858-0.619-0.047-4.909-6.79-11.336-9.55-7.136-0.298-7.647-5.28-16.752-6.752
EPS -0.32-0.31-0.38-0.22-0.3-0.27-0.66-0.26-0.31-0.082-0.011-0.8-0.84-0.62-0.32-0.2-0.059-0.14-0.2-0.1-0.12
EPS Diluted -0.32-0.31-0.38-0.22-0.3-0.27-0.66-0.26-0.31-0.082-0.011-0.8-0.84-0.61-0.32-0.2-0.057-0.14-0.2-0.1-0.12
EBITDA -65.962-72.221-81.32-38.68-59.968-56.356-125.906-40.406-49.402-4.17-21.197-136.843-144.083-105.656-57.608-32.885-3.012-23.007-37.371-17.723-20.695
EBITDA Ratio -4.569-5.302-3.698-2.376-7.936-7.143-10.812-3.604-2.452-0.1710.002-4.664-6.434-10.534-7.767-6.371-0.087-6.523-5.483-16.171-6.183